s20098 has been researched along with Disease Models, Animal in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 9 (18.75) | 29.6817 |
| 2010's | 30 (62.50) | 24.3611 |
| 2020's | 8 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Bialek, K; Bijak, M; Czarny, P; Kolodziej, L; Papp, M; Sliwinski, T; Synowiec, E; Szemraj, J; Wigner, P | 1 |
| Lad, KA; Maheshwari, A; Saxena, B | 1 |
| Jani, P; Pandya, N; Tandel, H; Vanza, J | 1 |
| An, Q; Chen, Y; Li, C; Li, J; Luo, Y; Song, R; Tong, A; Yang, Y; Zhou, L | 1 |
| Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D | 1 |
| Boudah, A; Jasmin, L; Rebai, R | 1 |
| Amin, N; Chen, F; Chen, S; Fang, M; Jin, W; Liu, J | 1 |
| Cao, Y; Long, J; Wang, F; Wang, Y | 1 |
| Atanasova, D; Atanasova, M; Ilieva, K; Kortenska, L; Tchekalarova, J | 2 |
| Cattaneo, A; Molteni, R; Paladini, MS; Racagni, G; Riva, MA; Rossetti, AC | 1 |
| Allaïli, N; Euvrard, M; Fossati, P; Franc, B; Gabriel, C; Lanfumey, L; Lehericy, S; Marday, T; Martin, V; Mocaër, E; Riffaud, A | 1 |
| Bouzinova, EV; Christiansen, SL; Højgaard, K; Wiborg, O | 1 |
| Atanasova, D; Atanasova, M; Kortenska, L; Lazarov, N; Tchekalarova, J | 1 |
| Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W | 1 |
| Atanasova, D; Galchev, T; Kortenska, L; Lazarov, N; Marinov, P; Shishmanova-Doseva, M; Tchekalarova, J | 1 |
| Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K | 1 |
| Carvalho, AF; Cha, DS; MacIsaac, SE; Mansur, RB; McIntyre, RS | 1 |
| Gupta, S; Sharma, B | 1 |
| Almeida, OF; Alves, ND; Beckers, J; Bessa, JM; Correia, JS; Irmler, M; Korostynski, M; Machado-Santos, AR; Mateus-Pinheiro, A; Morais, M; Patrício, P; Piechota, M; Pinto, L; Sousa, N; Stoffel, R | 1 |
| Bumgardner, AL; Fadel, JR; Gabriel, C; Grillo, CA; Hang, A; Macht, VA; Mocaër, E; Piroli, GG; Reagan, LP; Risher, M | 1 |
| Boulle, F; Gabriel, C; Lanfumey, L; Marday, S; Massart, R; Mocaer, E; Mongeau, R; Païzanis, E; Stragier, E; Zaidan, L | 1 |
| Gupta, S; Sharma, B; Singh, P | 1 |
| Noori, HR; Spanagel, R; Vengeliene, V | 1 |
| Gupta, S; Sharma, B; Sharma, BM; Singh, P | 1 |
| Boulle, F; Franc, B; Gabriel, C; Kenis, G; Koedam, K; Lanfumey, L; Mocaer, E; Mongeau, R; Rognan, D; Steinbusch, HW; van den Hove, DLA; Velthuis, H | 1 |
| Alper, F; Bayraktutan, Z; Diyarbakir, B; Durur-Karakaya, A; Durur-Subasi, I; Gundogdu, C; Karaman, A; Kose, D; Özbek-Bilgin, A; Topcu, A | 1 |
| Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E | 1 |
| Campbell, AM; Conboy, L; Diamond, DM; Gabriel, C; Mocaer, E; Park, CR; Sandi, C; Tanrikut, C; Zoladz, PR | 1 |
| Dhir, A; Kulkarni, SK | 1 |
| Popoli, M | 1 |
| Dagyte, G; Den Boer, JA; Gabriel, C; Luiten, PG; Meerlo, P; Mocaër, E; Postema, F; Trentani, A; Van der Zee, EA | 1 |
| David, DJ; Enhamre, E; Gabriel, C; Gardier, AM; Guilloux, JP; Hen, R; Mocaër, E; Rainer, Q; Xia, L | 1 |
| Dagyte, G; De Jager, T; Den Boer, JA; Gabriel, C; Luiten, PG; Mocaër, E; Van der Zee, EA | 1 |
| Dubois, M; El Yacoubi, M; Gabriel, C; Mocaër, E; Vaugeois, JM | 1 |
| Baulieu, EE; Bianchi, M; Gabriel, C; Ladurelle, N; Mocaër, E; Viggiano, A | 1 |
| Dobrek, Ł; Thor, PJ | 1 |
| Catalani, A; Cianci, S; Consolazione, M; Gabriel, C; Gaetani, S; Giovine, A; Laloux, C; Maccari, S; Mairesse, J; Malagodi, M; Mazzetta, A; Mennuni, G; Mocaër, E; Morley-Fletcher, S; Nicoletti, F; Silletti, V; van Camp, G; van Reeth, O; Zuena, AR | 1 |
| Girbig, D; Igl, BW; Lehmann, T; Obendorf, M; Patchev, VK; Prelle, K | 1 |
| Acuña-Castroviejo, D; Lauterbach, EC; Othman, Z; Srinivasan, V; Zakaria, R | 1 |
| Boyer, PA; Gruca, P; Mocaër, E; Papp, M | 1 |
| Barden, N; Labbé, M; Mocaër, E; Rochford, J; Shink, E; Vacher, R | 1 |
| Boyer, PA; de Bodinat, C; Delalleau, B; Mocaër, E | 1 |
| Gruca, P; Litwa, E; Mocaër, E; Papp, M | 1 |
| Fuchs, E; Schmelting, B; Simon, M | 1 |
| Bánki, MC | 1 |
| Armstrong, SM; Guardiola-Lemaitre, B; McNulty, OM; Redman, JR | 1 |
7 review(s) available for s20098 and Disease Models, Animal
| Article | Year |
|---|---|
The mechanism, efficacy, and tolerability profile of agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2014 |
Current investigational drugs for major depression.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dopamine; Drug Delivery Systems; Drugs, Investigational; Hormone Antagonists; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Nitric Oxide; Phytotherapy; Receptors, Neurotransmitter; Steroids | 2009 |
Agomelatine: innovative pharmacological approach in depression.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders | 2009 |
Agomelatine in depressive disorders: its novel mechanisms of action.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Humans; Melatonin; Receptors, Melatonin; Sleep Wake Disorders | 2012 |
[Development of a new antidepressant : agomelatine].
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder; Disease Models, Animal; Humans; Hypnotics and Sedatives; Melatonin; Receptor, Serotonin, 5-HT2C | 2005 |
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Tupaiidae | 2006 |
[Agomelatine: the first "melatoninergic" antidepressant].
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Hypnotics and Sedatives; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep | 2006 |
41 other study(ies) available for s20098 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure.
Topics: Acetamides; Animals; Antidepressive Agents; Brain; Cyclooxygenase 2; Disease Models, Animal; DNA Methylation; I-kappa B Kinase; Leukocytes, Mononuclear; Male; Naphthalenes; Promoter Regions, Genetic; Rats; Rats, Wistar; Stress, Psychological | 2022 |
Repositioning of an anti-depressant drug, agomelatine as therapy for brain injury induced by craniotomy.
Topics: Acetamides; Animals; Blood-Brain Barrier; Brain Injuries, Traumatic; Combined Modality Therapy; Decompressive Craniectomy; Disease Models, Animal; Drug Repositioning; Lipid Peroxidation; Nitric Oxide; Rats; Treatment Outcome | 2019 |
Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery.
Topics: Acetamides; Administration, Intranasal; Animals; Antidepressive Agents; Behavior Observation Techniques; Behavior, Animal; Blood-Brain Barrier; Delayed-Action Preparations; Depression; Disease Models, Animal; Drug Carriers; Drug Compounding; Goats; Humans; Nanoparticles; Nasal Mucosa; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Toxicity Tests | 2019 |
Scaffold hopping of agomelatine leads to enhanced antidepressant effects by modulation of gut microbiota and host immune responses.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Brain; Cytokines; Depression; Depressive Disorder; Disease Models, Animal; Food Preferences; Gastrointestinal Microbiome; Immunity; Inflammasomes; Male; Mice; Mice, Inbred C57BL; Stress, Psychological; Treatment Outcome | 2020 |
A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.
Topics: Acetamides; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Glaucoma; Gliosis; Melatonin; Neuroprotective Agents; Rats; Retina; Signal Transduction; Treatment Outcome | 2020 |
Agomelatine effects on fat-enriched diet induced neuroinflammation and depression-like behavior in rats.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Depression; Diet, High-Fat; Disease Models, Animal; Inflammation; Inflammation Mediators; Male; Oxidative Stress; Rats, Wistar | 2021 |
Agomelatine Softens Depressive-Like Behavior through the Regulation of Autophagy and Apoptosis.
Topics: Acetamides; Animals; Apoptosis; Autophagy; bcl-2-Associated X Protein; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Male; MAP Kinase Signaling System; Membrane Glycoproteins; Mice; Protein-Tyrosine Kinases; Stress, Psychological | 2021 |
Agomelatine prevents macrophage infiltration and brain endothelial cell damage in a stroke mouse model.
Topics: Acetamides; Animals; Blood-Brain Barrier; Brain; Cell Hypoxia; Cell Movement; Chemokine CCL2; Claudin-5; Disease Models, Animal; Down-Regulation; Endothelial Cells; Infarction, Middle Cerebral Artery; Macrophages; Mice; Permeability; Stroke; Tight Junction Proteins | 2021 |
Chronic agomelatine treatment alleviates icvAβ-induced anxiety and depressive-like behavior through affecting Aβ metabolism in the hippocampus in a rat model of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anxiety; Disease Models, Animal; Hippocampus; Rats | 2021 |
Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Disease Models, Animal; Genome; Hippocampus; Inflammation; Lipopolysaccharides; Male; Microarray Analysis; Rats; Rats, Sprague-Dawley; Transcription, Genetic | 2018 |
Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice.
Topics: Acetamides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Depressive Disorder; Disease Models, Animal; Disks Large Homolog 4 Protein; Gene Expression Regulation; Hippocampus; Humans; Memory Disorders; Mice; Microfilament Proteins; Nerve Tissue Proteins; Neuronal Plasticity; Stress, Psychological; Synapsins; Synaptophysin | 2017 |
Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; CLOCK Proteins; Depression; Disease Models, Animal; Male; Melatonin; Period Circadian Proteins; Rats; Rats, Wistar; Treatment Outcome | 2018 |
Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling.
Topics: Acetamides; Animals; Antidepressive Agents; Comorbidity; Depression; Disease Models, Animal; Hypnotics and Sedatives; Inflammation Mediators; Male; Rats; Rats, Wistar; Signal Transduction; Status Epilepticus; Treatment Outcome | 2018 |
Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus.
Topics: Acetamides; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Gene Expression Regulation; Hippocampus; Hypnotics and Sedatives; Male; Rats; Rats, Sprague-Dawley; Stress, Psychological | 2018 |
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Topics: Acetamides; Alzheimer Disease; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Exploratory Behavior; Hippocampus; Male; Maze Learning; Melatonin; Memory Disorders; Rats; Rats, Sprague-Dawley; Streptozocin | 2019 |
Agomelatine alleviates neuronal loss through BDNF signaling in the post-status epilepticus model induced by kainic acid in rat.
Topics: Acetamides; Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Electroencephalography; Epilepsy, Temporal Lobe; Hippocampus; Kainic Acid; Lacosamide; Male; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Seizures; Signal Transduction; Status Epilepticus | 2019 |
Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Bicuculline; Diazepam; Disease Models, Animal; Drug Interactions; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Male; Mice; Mice, Inbred C57BL; Motor Activity; Obsessive-Compulsive Disorder; Piperazines; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease.
Topics: Acetamides; Animals; Benzaldehydes; Disease Models, Animal; Female; Huntington Disease; Male; Maze Learning; Melatonin; Motor Activity; Nitro Compounds; Propionates; Rats; Rats, Wistar; TRPV Cation Channels | 2014 |
Differential and converging molecular mechanisms of antidepressants' action in the hippocampal dentate gyrus.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Dentate Gyrus; Depressive Disorder; Disease Models, Animal; Fluoxetine; Gene Expression; Imipramine; Male; Neurons; Random Allocation; Rats, Wistar; Stress, Psychological; Thiazepines; Uncertainty | 2015 |
Repeated restraint stress-induced atrophy of glutamatergic pyramidal neurons and decreases in glutamatergic efflux in the rat amygdala are prevented by the antidepressant agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Atrophy; Basolateral Nuclear Complex; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Glutamic Acid; Male; Neuronal Plasticity; Pyramidal Cells; Rats, Sprague-Dawley; Restraint, Physical; Stress, Psychological | 2015 |
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine.
Topics: Acetamides; Affective Symptoms; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Epigenesis, Genetic; Hippocampus; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Psychomotor Agitation; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction; Stress, Psychological | 2014 |
Melatonin receptor and KATP channel modulation in experimental vascular dementia.
Topics: Acetamides; Animals; Arterial Pressure; Brain; Dementia, Vascular; Disease Models, Animal; Hypertension, Renovascular; KATP Channels; Male; Maze Learning; Neuroprotective Agents; Nicorandil; Nootropic Agents; Oxidative Stress; Random Allocation; Rats, Wistar; Receptors, Melatonin; Spatial Memory | 2015 |
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals; Choice Behavior; Circadian Rhythm; Disease Models, Animal; Indoles; Male; Melatonin; Motor Activity; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists | 2015 |
Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia.
Topics: Acetamides; Acetylcholinesterase; Analysis of Variance; Animals; Arterial Occlusive Diseases; Brain; Catalase; Dementia, Vascular; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Male; Malondialdehyde; Maze Learning; Mice; Neuroprotective Agents; Superoxide Dismutase; Time Factors; Vinca Alkaloids | 2015 |
Behavioral and neurochemical characterization of TrkB-dependent mechanisms of agomelatine in glucocorticoid receptor-impaired mice.
Topics: Acetamides; Animals; Antidepressive Agents; Azepines; Benzamides; Brain-Derived Neurotrophic Factor; Cell Proliferation; Depressive Disorder; Disease Models, Animal; Fear; Hippocampus; Male; Mice, Transgenic; Motor Activity; Receptor, trkB; Receptors, Glucocorticoid; Single-Blind Method; Social Behavior | 2016 |
A novel approach to contrast-induced nephrotoxicity: the melatonergic agent agomelatine.
Topics: Acetamides; Animals; Contrast Media; Cytokines; Disease Models, Animal; Female; Glutathione; Interleukin-6; Kidney; Malondialdehyde; NF-kappa B; Oxidative Stress; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Selective Serotonin Reuptake Inhibitors; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2016 |
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Amines; Animals; Antineoplastic Agents; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Hypnotics and Sedatives; Idazoxan; Male; Motor Activity; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Rats; Rats, Sprague-Dawley; Thiophenes | 2017 |
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats.
Topics: Acetamides; Analysis of Variance; Animals; Antidepressive Agents; Corticosterone; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Hippocampus; Learning Disabilities; Memory Disorders; Neural Cell Adhesion Molecule L1; Rats; Rats, Sprague-Dawley; Sialic Acids; Space Perception; Stress, Psychological | 2009 |
The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats.
Topics: Acetamides; Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; Body Weight; Bromodeoxyuridine; Corticosterone; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein; Eating; Electroshock; Gene Expression Regulation; Hippocampus; Ki-67 Antigen; Male; Microtubule-Associated Proteins; Neurogenesis; Neurons; Neuropeptides; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stress, Psychological | 2010 |
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cell Proliferation; Circadian Rhythm; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Mice, Inbred C57BL; Motor Activity; Neurogenesis; Neurons; Serotonin 5-HT2 Receptor Antagonists | 2012 |
Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain.
Topics: Acetamides; Animals; Antidepressive Agents; Brain Chemistry; Chronic Disease; Depressive Disorder; Disease Models, Animal; Male; Rats; Rats, Wistar; Stress, Psychological; Synapsins | 2011 |
Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.
Topics: Acetamides; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Locomotion; Mice | 2011 |
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
Topics: Acetamides; Amygdala; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognition; Cytoskeleton; Depression; Disease Models, Animal; Hippocampus; Male; Microtubules; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Synapses | 2012 |
The influence of melatonin and agomelatine on urodynamic parameters in experimental overactive bladder model--preliminary results.
Topics: Acetamides; Animals; Case-Control Studies; Central Nervous System Depressants; Disease Models, Animal; Female; Hypnotics and Sedatives; Melatonin; Random Allocation; Rats; Rats, Wistar; Urinary Bladder, Overactive; Urodynamics | 2011 |
Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
Topics: Acetamides; Analysis of Variance; Animals; Animals, Newborn; Arousal; Autoradiography; Chronobiology Disorders; Disease Models, Animal; Drug Administration Schedule; Electroencephalography; Electromyography; Female; Hippocampus; Hypnotics and Sedatives; Male; Movement Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Melatonin; Restraint, Physical; Sleep Wake Disorders; Thiophenes | 2013 |
Endpoints of drug discovery for menopausal vasomotor symptoms: interpretation of data from a proxy of disease.
Topics: Acetamides; Amines; Animals; Body Temperature Regulation; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal; Diurnal Enuresis; Drug Discovery; Estradiol; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Hypnotics and Sedatives; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Skin Temperature; Venlafaxine Hydrochloride | 2012 |
Effect of agomelatine in the chronic mild stress model of depression in the rat.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Chronotherapy; Depression; Disease Models, Animal; Male; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Receptors, Serotonin; Stress, Physiological | 2003 |
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.
Topics: Acetamides; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Desipramine; Disease Models, Animal; In Situ Hybridization; Male; Maze Learning; Melatonin; Mice; Mice, Transgenic; Receptors, Glucocorticoid; Swimming; Telemetry; Time Factors | 2005 |
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Arousal; Brain; Buspirone; Chronotherapy; Conditioning, Classical; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroshock; Exploratory Behavior; Fear; Male; Maze Learning; Melatonin; Rats; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Thiophenes; Vocalization, Animal | 2006 |
Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).
Topics: Acetamides; Animals; Circadian Rhythm; Disease Models, Animal; Hypnotics and Sedatives; Male; Melatonin; Rats; Sleep Wake Disorders | 1993 |